{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:20:18Z","timestamp":1785817218634,"version":"3.56.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52033006"],"award-info":[{"award-number":["52033006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52233007"],"award-info":[{"award-number":["52233007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jconrel.2024.09.040","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:49:52Z","timestamp":1727830192000},"page":"767-775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["PSMA and Sigma-1 receptor dual-targeted peptide mediates superior radionuclide imaging and therapy of prostate cancer"],"prefix":"10.1016","volume":"375","author":[{"given":"Zhenyuan","family":"Huangfu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangtao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghua","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.09.040_bb0005","first-page":"1","article-title":"Precision radiation opens a new window on cancer therapy","author":"Senior","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0010","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics in oncology: current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0015","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S1470-2045(19)30821-6","article-title":"Radiotheranostics: a roadmap for future development","volume":"21","author":"Herrmann","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0020","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0025","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1021\/cr500171e","article-title":"Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications","volume":"115","author":"Banerjee","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0030","doi-asserted-by":"crossref","first-page":"12004","DOI":"10.1021\/acs.chemrev.3c00456","article-title":"Theranostic nuclear medicine with gallium-68, lutetium-177, copper-64\/67, actinium-225, and lead-212\/203 radionuclides","volume":"123","author":"Morgan","year":"2023","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0035","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.semnuclmed.2019.02.008","article-title":"PSMA-targeted radiopharmaceuticals for imaging and therapy","volume":"49","author":"Wester","year":"2019","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0040","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1053\/j.semnuclmed.2019.02.002","article-title":"Molecular imaging and theranostics-a multidisciplinary approach","volume":"49","author":"Farolfi","year":"2019","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0045","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.addr.2022.114538","article-title":"Imaging-guided targeted radionuclide tumor therapy: from concept to clinical translation","volume":"190","author":"Sun","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0050","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e16701","article-title":"Real-world analysis of peptide receptor radionuclide therapy (PRRT) in the treatment of neuroendocrine tumors","volume":"38","author":"Chau","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0055","doi-asserted-by":"crossref","first-page":"940","DOI":"10.7150\/thno.91268","article-title":"Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023","volume":"14","author":"di Santo","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2024.09.040_bb0060","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/RLU.0000000000001240","article-title":"Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer","volume":"41","author":"Rahbar","year":"2016","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0065","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0070","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2214\/AJR.18.20845","article-title":"Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"213","author":"Yadav","year":"2019","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0075","article-title":"Emerging theranostics for prostate cancer and a model of prostate-specific membrane antigen therapy","volume":"311","author":"Jewell","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.jconrel.2024.09.040_bb0080","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with 177Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomized, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0085","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0090","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-med-081522-031439","article-title":"Prostate-specific membrane antigen: gateway to management of advanced prostate cancer","volume":"75","author":"Unterrainer","year":"2024","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0095","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrurol.2016.26","article-title":"Current use of PSMA-PET in prostate cancer management","volume":"13","author":"Maurer","year":"2016","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0100","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1158\/1078-0432.CCR-20-0209","article-title":"Mechanistic insights for optimizing PSMA radioligand therapy","volume":"26","author":"Ravi Kumar","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0105","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1021\/acs.bioconjchem.8b00556","article-title":"Single low-dose injection of Evans blue modified PSMA-617 radioligand therapy eliminates prostate-specific membrane antigen positive tumors","volume":"29","author":"Wang","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0110","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.7150\/thno.40482","article-title":"Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity","volume":"10","author":"Deberle","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2024.09.040_bb0115","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1021\/acs.molpharmaceut.8b00720","article-title":"Enhancing treatment efficacy of 177Lu-PSMA-617 with the conjugation of an abumin-binding motif: preclinical dosimetry and endoradiotherapy studies","volume":"15","author":"Kuo","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0120","first-page":"1","article-title":"Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties","author":"Hou","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2024.09.040_bb0125","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1007\/s00259-023-06229-w","article-title":"Development of 177Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression","volume":"50","author":"Wen","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2024.09.040_bb0130","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1080\/17425255.2020.1801633","article-title":"Albumin-based drug designs for pharmacokinetic modulation","volume":"16","author":"Pilati","year":"2020","journal-title":"Expert. Opin. Drug. Met."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0135","doi-asserted-by":"crossref","first-page":"656","DOI":"10.2967\/jnumed.118.221150","article-title":"Albumin-binding PSMA ligands: implications for expanding the therapeutic window","volume":"60","author":"Kelly","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0140","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2967\/jnumed.123.265524","article-title":"Albumin-binding and conventional PSMA ligands in combination with 161Tb: biodistribution, dosimetry, and preclinical therapy","volume":"64","author":"Tschan","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0145","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00259-018-4004-5","article-title":"Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors","volume":"45","author":"Kelly","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2024.09.040_bb0150","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/anie.201710232","article-title":"Efficient uptake of 177Lu-porphyrin-PEG nanocomplexes by tumor mitochondria for multimodal-imaging-guided combination therapy","volume":"57","author":"Yu","year":"2018","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0155","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1021\/acs.jmedchem.5b01210","article-title":"Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors","volume":"59","author":"Benesova","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0160","article-title":"Prostate-specific membrane antigen targeted starPEG nanocarrier for imaging and therapy of prostate cancer","volume":"2304618","author":"Meher","year":"2024","journal-title":"Adv. Healthc Mater, n\/a"},{"key":"10.1016\/j.jconrel.2024.09.040_bb0165","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jconrel.2023.06.032","article-title":"RGD-directed 24 nm micellar docetaxel enables elevated tumor-liver ratio, deep tumor penetration and potent suppression of solid tumors","volume":"360","author":"Yan","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.09.040_bb0170","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1021\/acs.molpharmaceut.8b00152","article-title":"Preclinical development of novel PSMA-targeting radioligands: modulation of albumin-binding properties to improve prostate cancer therapy","volume":"15","author":"Umbricht","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0175","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00044-022-03002-w","article-title":"Optimization of the dipeptide motifs in the PSMA ligands linker structure: synthesis and in vitro evaluation","volume":"32","author":"Uspenskaya","year":"2023","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0180","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.nucmedbio.2013.11.006","article-title":"A heterodimeric [RGD-Glu-[64Cu-NO2A]-6-Ahx-RM2] alphavbeta3\/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors","volume":"41","author":"Durkan","year":"2014","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0185","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/pros.22784","article-title":"Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer","volume":"74","author":"Eder","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.jconrel.2024.09.040_bb0190","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3390\/ph15030383","article-title":"Radiosynthesis and preclinical evaluation of bispecific PSMA\/FAP heterodimers for tumor imaging","volume":"15","author":"Hu","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jconrel.2024.09.040_bb0195","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/pharmaceutics11070358","article-title":"Synthesis and preclinical evaluation of radio-iodinated GRPR\/PSMA bispecific heterodimers for the theranostics application in prostate cancer","volume":"11","author":"Abouzayed","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2024.09.040_bb0200","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3390\/molecules28031088","article-title":"Synthesis and preclinical evaluation of three novel 68Ga-labeled bispecific PSMA\/FAP-targeting tracers for prostate cancer imaging","volume":"28","author":"Verena","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2024.09.040_bb0205","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2174\/157015908787386113","article-title":"Pharmacology and therapeutic potential of sigma1 receptor ligands","volume":"6","author":"Cobos","year":"2008","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0210","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.bmcl.2008.01.109","article-title":"PB183, a sigma receptor ligand, as a potential PET probe for the imaging of prostate adenocarcinoma","volume":"18","author":"Colabufo","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0215","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/med.20218","article-title":"Sigma receptors and their ligands in cancer biology: overview and new perspectives for cancer therapy","volume":"32","author":"Megalizzi","year":"2012","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0220","first-page":"2703","article-title":"Potential applications for sigma receptor ligands in cancer diagnosis and therapy","volume":"2015","author":"van Waarde","year":"1848","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2024.09.040_bb0225","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1158\/0008-5472.CAN-16-1055","article-title":"Sigma1 targeting to suppress aberrant androgen receptor signaling in prostate cancer","volume":"77","author":"Thomas","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0230","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1055\/s-0043-1775744","article-title":"A practical guide to sigma-1 receptor positron emission tomography\/magnetic resonance imaging: a new clinical molecular imaging method to identify peripheral pain generators in patients with chronic pain","volume":"27","author":"Shen","year":"2023","journal-title":"Semin. Musculoskelet. Radiol."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0235","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.1016\/j.biomaterials.2012.07.012","article-title":"Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice","volume":"33","author":"Guo","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.09.040_bb0240","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijpharm.2015.12.055","article-title":"A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor","volume":"499","author":"Fitzgerald","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0245","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1039\/C6TB00082G","article-title":"Anisamide-targeted gold nanoparticles for siRNA delivery in prostate cancer \u2013 synthesis, physicochemical characterisation and in vitro evaluation","volume":"4","author":"Fitzgerald","year":"2016","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2024.09.040_bb0250","doi-asserted-by":"crossref","first-page":"1603451","DOI":"10.1002\/adma.201603451","article-title":"Targeting nanocarriers with anisamide: fact or artifact?","volume":"29","author":"Dasargyri","year":"2017","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0255","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.3390\/cancers13164023","article-title":"PSMA theranostics: current landscape and future outlook","volume":"13","author":"Zhang","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jconrel.2024.09.040_bb0260","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jconrel.2022.08.048","article-title":"IL-11Ralpha-targeted nanostrategy empowers chemotherapy of relapsed and patient-derived osteosarcoma","volume":"350","author":"Jiang","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.09.040_bb0265","first-page":"408","article-title":"Sigma-1 and Sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines","volume":"55","author":"Vilner","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0270","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.canlet.2005.11.011","article-title":"The expression and functional characterization of sigma (sigma) 1 receptors in breast cancer cell lines","volume":"242","author":"Aydar","year":"2006","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0275","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3390\/ph12030114","article-title":"Lutathera\u00ae: the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy","volume":"12","author":"Hennrich","year":"2019","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jconrel.2024.09.040_bb0280","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1053\/j.semnuclmed.2022.02.004","article-title":"The impact of radiopharmaceutical therapy on renal function","volume":"52","author":"Park","year":"2022","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0285","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2967\/jnumed.120.250738","article-title":"Novel 177Lu-labeled albumin-binder-conjugated PSMA-targeting agents with extremely high tumor uptake and enhanced tumor-to-kidney absorbed dose ratio","volume":"62","author":"Kuo","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0290","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0295","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1007\/s00259-020-05150-w","article-title":"A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals","volume":"48","author":"Kalidindi","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jconrel.2024.09.040_bb0300","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.nucmedbio.2016.07.009","article-title":"A DOTA based bisphosphonate with an albumin binding moiety for delayed body clearance for bone targeting","volume":"43","author":"Meckel","year":"2016","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0305","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1053\/j.semnuclmed.2019.07.002","article-title":"Economics of new molecular targeted personalized radiopharmaceuticals","volume":"49","author":"Cutler","year":"2019","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0310","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","article-title":"Covalent targeted radioligands potentiate radionuclide therapy","volume":"630","author":"Cui","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2024.09.040_bb0315","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10585-018-9878-x","article-title":"Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases","volume":"34","author":"Kasoha","year":"2017","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.jconrel.2024.09.040_bb0320","doi-asserted-by":"crossref","first-page":"7664","DOI":"10.3748\/wjg.v26.i48.7664","article-title":"Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis","volume":"26","author":"Chen","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2024.09.040_bb0325","article-title":"Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS One"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924006503?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924006503?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T13:07:42Z","timestamp":1745586462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924006503"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":65,"alternative-id":["S0168365924006503"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.09.040","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSMA and Sigma-1 receptor dual-targeted peptide mediates superior radionuclide imaging and therapy of prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.09.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}